Dr. Tanya Ramey serves as Chief Medical Officer at Usona Institute, where she leads the organization’s medical and clinical programs focused on developing safe and effective psychedelic therapies for depression and related mental health conditions. She ensures that Usona’s research upholds the highest standards of scientific rigor, clinical integrity, and patient safety.
With over three decades of experience in psychiatry and neuroscience, Dr. Ramey has held senior leadership roles in academia, industry, and government. She was the head of the early clinical development for psychiatry at Pfizer and developed many marketed antidepressants and antipsychotics. Earlier in her career she led global clinical programs in neuroscience at Eli Lilly. She later joined the National Institute on Drug Abuse (NIDA), where she advanced innovations in clinical trials methodology in substance use disorders and was an architect of collaborative novel approaches to drug development in mental health and addiction.
Dr. Ramey earned her MD from Altai State Medical University and a PhD in Psychiatric Genetics from the Russian Academy of Medical Sciences. Earlier in her career, she served as a professor of psychiatry at Moscow State University of Medicine and Dentistry. She is ECFMG-certified in the United States and was trained in a psychiatry residency program at Vanderbilt University, where she refined her clinical expertise and deepened her dedication to evidence-based psychiatric care.
As a founding member of the International Society for CNS Clinical Trials and Methodology, Dr. Ramey combines scientific insight with compassionate leadership to advance Usona’s mission of transforming mental health care through innovation, collaboration, and human understanding.